Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...

This is no reason to panic.

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...

Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Some patients dropped out of the trial early because they had lost so much weight.

Dec 1 (Reuters) - Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound ...

We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...